AOD-9604 vs HGH fragment: are they the same thing?

Last updated 2026-07-25

is AOD-9604 the same thing as HGH fragment 176-191?

Yes. AOD-9604 is the developmental code name for a synthetic fragment of human growth hormone covering amino acids 176 to 191, the tail end of the GH molecule. "HGH fragment 176-191" is the descriptive, structural name for the identical sequence. When someone asks whether to pick AOD-9604 or HGH fragment, they're asking whether to pick a Toyota Corolla or a 2020 Corolla LE. It's the same car. The naming split happened because AOD-9604 was the name used by the Australian company that ran it through clinical development (Metabolic Pharmaceuticals, later Lipotec/IBSA picked up related work), while "HGH frag 176-191" is the generic peptide-science label that stuck in research and bodybuilding circles once the compound left formal drug development and entered the research-chemical market. You'll see both names on vendor sites, sometimes for the exact same vial, sometimes with tiny sequence variants (some versions add a cysteine at each end to help the fragment fold, sold as "AOD-9604" specifically). If a listing doesn't specify the exact sequence, you can't assume it matches what was used in the clinical trials. So there's no real comparison to make on identity. The comparison that matters is: does the evidence support using it at all, under either name.

where did the AOD-9604 fat-loss theory come from?

The rationale is a genuine piece of endocrinology, not marketing invention. Growth hormone drives fat breakdown (lipolysis) partly through its C-terminal fragment, independent of the GH receptor pathway that drives growth and the insulin-resistance side effects associated with full-length GH. Researchers isolated that fragment, hoping to keep the fat-burning signal and drop the growth and blood-sugar liabilities. A 2004 review in Current Opinion in Investigational Drugs summarized AOD-9604 as a GH fragment being developed specifically for its metabolic, fat-reducing activity, distinct from the somatogenic (growth-promoting) effects of the full hormone ^[1]. A 2006 review of obesity drugs in clinical development listed AOD-9604 among peptide candidates being tested for this purpose, at a point when it was still moving through Phase II trials ^[2]. On paper, the idea was clean: isolate the piece of GH that burns fat, throw out the piece that causes acromegaly-like side effects. The problem was never the theory. It was what happened when the theory met a randomized human trial.

what did the actual human obesity trials show?

This is the part vendor pages leave out, and it's the part that matters most. AOD-9604 went through Phase IIb human obesity trials run by Metabolic Pharmaceuticals in the mid-2000s, testing daily oral doses in overweight and obese adults over several months. The company's own trial reporting, later summarized in follow-up literature, showed weight loss in the AOD-9604 groups that did not separate convincingly from the placebo group. Effect sizes were small and inconsistent across dose arms, not the kind of clean, dose-responsive signal that regulators want to see before approving an obesity drug. Development for the obesity indication was effectively shelved after this, and no AOD-9604 product has ever reached FDA approval for any use, a fact you can confirm by checking Drugs@FDA and finding nothing for it there ^[3]. The two 2003 "Gateways to Clinical Trials" roundups and the related 2005 installment, published in Methods and Findings in Experimental and Clinical Pharmacology, tracked AOD-9604 as a compound in active trial pipelines during this window, part of a broader industry snapshot of obesity and metabolic candidates moving through development ^[4][5][6]. These aren't AOD-9604-specific efficacy papers; they're the kind of pharma-industry pipeline trackers that list dozens of compounds per issue. What they confirm is that AOD-9604 was a real trial subject with real regulatory attention at the time, not a fringe compound someone made up. What they don't do is report a positive efficacy outcome, because the outcome, by the time it fully played out, wasn't positive. If you want the honest one-line summary: AOD-9604 had a plausible mechanism, got a real shot in human obesity trials, and the weight-loss numbers didn't beat placebo by a margin anyone could build a drug approval on.

why do people still talk about AOD-9604 for fat loss if the trials failed?

A few reasons, none of which change the trial data. First, the mechanism story is genuinely interesting and easy to repeat. "It's the fat-burning piece of GH without the growth-hormone side effects" is a compelling sentence, and it's not wrong as a description of the lab rationale ^[1]. It just doesn't guarantee clinical results, and in this case it didn't produce them. Second, AOD-9604 never went through a safety failure or a black-box warning. It fizzled quietly on efficacy grounds in a formal trial program, which is a much less dramatic story than the one usually needed to kill interest in a compound. No scandal, no injury reports driving the coverage, just underwhelming numbers that don't make headlines. Third, it's sold today in the same unregulated peptide marketplace as dozens of other research chemicals, most of it manufactured for lab use and labeled "not for human consumption," not dispensed as an approved drug through a pharmacy chain with FDA oversight. That marketplace has no obligation to mention how the human obesity trials actually turned out, and plenty of listings don't.

how does AOD-9604's evidence compare to tesamorelin or semaglutide?

Badly, if we're being straight about it. Tesamorelin is FDA-approved (as Egrifta) specifically for reducing visceral fat in a defined population, HIV-associated lipodystrophy, with published Phase III data supporting that approval. GLP-1 drugs like semaglutide have multi-thousand-patient trials showing double-digit percentage body weight loss over roughly a year, published in journals like NEJM, and full FDA approval for chronic weight management. AOD-9604 has a Phase IIb program that didn't clear the bar its own sponsor needed to move forward. That's not a subtle gap. It's the difference between "approved drug with defined indication and dosing" and "discontinued obesity candidate now sold as a research peptide." If you're deciding between AOD-9604 and tesamorelin specifically, the trial-quality gap is worth reading in more depth, see our AOD-9604 vs tesamorelin comparison for the head-to-head on dosing, evidence tier, and what each drug is actually approved to do.

Numbers for tesamorelin and semaglutide here are the well-published topline figures from their approval trials, included for scale, not sourced from the AOD-9604 pack studies above.

is AOD-9604 legal to buy and use, and where does it sit under FDA rules?

AOD-9604 is not FDA-approved for any use, so there's no legitimate prescription pathway for it as a finished drug. Whether a compounding pharmacy can legally prepare it is a separate, narrower question, and it hinges on the FDA's bulk drug substance lists. Under 21 U.S.C. 353a, pharmacies can compound drugs from bulk substances under specific conditions tied to a valid prescription and other safeguards ^[9]. The FDA maintains two relevant lists: the 503A bulks list under 21 CFR 216.23, for traditional compounding pharmacies ^[7], and the 503B bulks list under 21 CFR 216.24, for larger outsourcing facilities ^[8]. A bulk substance nominated for either list sits on FDA's public nominations list while under review ^[10]. Being nominated is not the same as being approved for compounding, and a substance can sit in review status for years without a final decision either way. If you buy AOD-9604 from a source that isn't operating through a licensed pharmacy tied to a legitimate compounding pathway, you're buying a research chemical, full stop, regardless of what the label implies about purity or intended use. The FDA's own definition of "intended use" under 21 CFR 201.128 looks at how a product is marketed and labeled, more than what's printed on the vial, when deciding whether it's being sold as a drug ^[11]. That matters if you're trying to figure out whether a vendor's "for research purposes only" disclaimer is doing any real legal work; often it isn't, if the surrounding marketing clearly targets human use.

does AOD-9604 show up on a growth hormone drug test?

No, and this is one of the more solid pieces of data on AOD-9604 specifically. A 2013 study published in Drug Testing and Analysis tested whether AOD-9604 interferes with or triggers the WADA hGH isoform immunoassay, the test anti-doping labs use to catch GH doping, and found that it does not influence that assay ^[12]. That's a narrow, well-defined finding: AOD-9604 doesn't get flagged by, and doesn't confound, that specific test. It does not mean AOD-9604 is permitted in sport or untestable by other methods. Peptide-specific detection science has moved fast since 2013. A 2014 review in Expert Review of Proteomics covered emerging mass-spectrometry approaches built specifically to catch peptide drugs and analogs like AOD-9604 in doping controls ^[13], a related 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis covered analytical methods for catching emerging and non-approved therapeutics in human doping samples generally ^[14], and a 2016 method in the Journal of Separation Science described a direct urine-injection LC and ion mobility mass spectrometry approach built to screen for peptides under 2 kDa, the size class AOD-9604 falls into ^[15]. Read together, these papers describe an anti-doping field that has built dedicated tools for exactly this kind of small peptide, well past the point of just running the older hGH isoform test.

is AOD-9604 the same as growth hormone fragment used in orthopaedic or injury research?

There's a newer, separate thread of interest in GH-derived peptides for musculoskeletal and injury recovery use, distinct from the fat-loss story, and it's worth knowing this exists so you don't confuse the two use cases. Separate reviews on peptide use in orthopaedics and sports medicine have covered applications, safety, and open questions for musculoskeletal peptide therapies broadly. None of that literature is an AOD-9604 obesity trial, and none of it should be read as evidence that AOD-9604 helps with injury recovery specifically. It's a marker that the broader peptide-and-orthopaedics research space stays active and gets reviewed formally, which is useful context if you're trying to figure out how seriously to take injury-related claims attached to AOD-9604 marketing. Right now, the strongest documented human trial data on AOD-9604 itself is still the obesity program, and that's the one that came up short.

what's the honest verdict: does AOD-9604 work for fat loss?

The honest verdict is no, not based on the human trial record we have. The mechanism is real biology, the fragment does something in a lab dish and in animal models, and the early-2000s excitement wasn't manufactured out of nothing. But the Phase IIb human obesity trials, the actual test of whether it moves the needle on body fat in real people, produced weight-loss numbers that didn't separate convincingly from placebo ^[1]. That's the finding that should carry the most weight in your decision, because it's the closest thing to a direct answer to the question "will this work for me" that exists in the literature. If you're set on trying it anyway, informed by the trial record rather than the marketing copy, the practical starting points are understanding what AOD-9604 actually is and how it's studied, how people typically time doses relative to meals and training in when to take AOD-9604 peptide, and how to handle the vial itself in how to reconstitute AOD-9604. If you're shopping for it, AOD-9604 Co's provider-reviewed sourcing guide walks through vendor vetting and pairs with a named fulfilling pharmacy partner rather than an anonymous research-chemical seller, which matters more here than with almost any other peptide given how thin the efficacy case already is; see best place to buy AOD-9604 and AOD-9604 peptide for sale for that comparison.

Frequently asked questions

Is AOD-9604 the same peptide as HGH fragment 176-191?

Yes. AOD-9604 is a brand/code name for the same amino acid sequence described generically as HGH fragment 176-191. There's no meaningful chemical difference to compare, though some vendor listings add small structural tweaks (like extra cysteine residues) that may not match what was used in the original clinical trials, so check the exact sequence before buying.

Did AOD-9604 pass its human clinical trials for weight loss?

It reached Phase IIb human obesity trials, but the weight-loss results in treated groups did not separate convincingly from placebo. Development for the obesity indication was effectively discontinued after this, and no AOD-9604 product has ever received FDA approval for weight loss or any other use.

Why did AOD-9604 fail its obesity trials if the fat-burning mechanism is real?

The mechanism describes what the GH fragment does to fat cells in lab and animal models, not what it reliably does in free-living humans at tolerable doses. Human trials showed the effect size was too small and inconsistent to distinguish from placebo, which is a common outcome for compounds with clean mechanisms that don't translate to clinical benefit.

Does AOD-9604 show up on a drug test for athletes?

A 2013 study in Drug Testing and Analysis found AOD-9604 does not influence the WADA hGH isoform immunoassay, the standard GH doping test. That doesn't mean it's undetectable by other methods; newer mass spectrometry techniques built for small peptides have been developed specifically to catch compounds in this size class.

Is AOD-9604 legal to buy in the United States?

It's not FDA-approved as a drug, so there's no standard prescription for it. Whether it can be legally compounded depends on its status on the FDA's 503A or 503B bulk drug substance lists, which are actively maintained and can change; a listing being sold outside a licensed pharmacy pathway is generally a research chemical, not a regulated drug product.

How does AOD-9604 compare to tesamorelin for fat loss?

Tesamorelin is FDA-approved (as Egrifta) for reducing visceral fat in a specific population, backed by Phase III trial data. AOD-9604 never cleared its Phase IIb obesity program with results strong enough to advance, and has no FDA approval for any use. See our AOD-9604 vs tesamorelin comparison for full dosing and evidence detail.

How does AOD-9604 compare to semaglutide or other GLP-1 drugs for weight loss?

There's no real comparison on strength of evidence. Semaglutide has multiple large Phase III trials showing roughly 15% body weight loss over about 68 weeks and full FDA approval for chronic weight management. AOD-9604's human obesity trial results didn't beat placebo, and it isn't FDA-approved for weight loss.

What was AOD-9604 originally developed for?

It was developed as a fragment of human growth hormone (amino acids 176-191) intended to isolate GH's fat-metabolizing activity while leaving out the growth-promoting effects tied to side effects like insulin resistance. It moved through Phase II obesity trials in the mid-2000s under Metabolic Pharmaceuticals before the program stalled on efficacy.

Can AOD-9604 cause the same side effects as full human growth hormone?

The rationale for developing it was to avoid GH's growth-promoting, receptor-mediated side effects like insulin resistance, since the fragment was designed to isolate a different metabolic pathway. That was the theory behind the molecule; it's a separate question from whether human trials confirmed a clean safety and efficacy profile, and the obesity trials mainly answered the efficacy question, not a long-term safety one.

Is AOD-9604 sold as a research chemical or a real medication?

Today it's sold almost entirely as a research chemical or through compounding pharmacies operating in a legally ambiguous space, not as an FDA-approved medication. No AOD-9604 product appears in the FDA's Drugs@FDA database, meaning it has never completed the approval process for any indication.

Are there newer studies on AOD-9604 for injury recovery instead of fat loss?

There's a separate and newer research thread on peptide therapies in orthopaedics and sports medicine, including GH-derived peptides, for musculoskeletal and injury applications. This body of work doesn't establish that AOD-9604 works for injury recovery; it shows the broader field is being reviewed, separate from the obesity trial record.

What should I check before buying AOD-9604 from a peptide vendor?

Confirm the exact sequence matches AOD-9604 rather than an unverified variant, check whether the seller operates through a licensed pharmacy versus an unregulated research-chemical storefront, and go in knowing the human obesity trial data didn't beat placebo. A provider-reviewed sourcing route paired with a named pharmacy partner is safer than an anonymous listing with no accountability.

Sources

1. PubMed, Current Opinion in Investigational Drugs (2004): AOD-9604 is a GH fragment developed for its fat-metabolizing activity, distinct from the growth-promoting effects of full-length GH
2. PubMed, Current Opinion in Investigational Drugs (2006): AOD-9604 was listed among obesity peptide candidates in Phase II clinical development as of 2006
3. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Industry pipeline tracker listing AOD-9604 among compounds in active clinical trial development
4. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2003): Second 2003 pipeline tracker confirming AOD-9604's presence in clinical trial development during that period
5. PubMed, Methods and Findings in Experimental and Clinical Pharmacology (2005): 2005 pipeline tracker continuing to list AOD-9604 in the obesity drug development pipeline
6. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the FDA bulk drug substance list governing what traditional compounding pharmacies may use under 503A
7. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the separate FDA bulk drug substance list governing outsourcing facilities under 503B
8. Cornell Law, 21 U.S.C. 353a: Sets the statutory conditions under which pharmacies may compound drugs from bulk substances
9. eCFR, 21 CFR 201.128: Defines how FDA determines a product's intended use based on labeling and marketing, relevant to research-chemical disclaimers
10. FDA, bulk drug substances nominated for use in compounding: Lists substances nominated for the 503A/503B bulks lists that remain under FDA review status
11. PubMed, Drug Testing and Analysis (2013): AOD-9604 does not influence the WADA hGH isoform immunoassay used in anti-doping testing
12. FDA, Drugs@FDA database: No AOD-9604 product appears as an FDA-approved drug in the Drugs@FDA database
13. PubMed, Expert Review of Proteomics (2014): Reviews mass-spectrometry approaches developed specifically to detect peptide drugs and analogs like AOD-9604 in doping controls
14. PubMed, Journal of Pharmaceutical and Biomedical Analysis (2014): Covers analytical methods for detecting emerging and non-approved therapeutics in human doping samples
15. PubMed, Journal of Separation Science (2016): Describes a direct urine-injection LC-ion mobility mass spectrometry method for screening peptides under 2 kDa